search
Back to results

Antigen Rapid Test Screening to Prevent SARS-CoV-2 Transmission (COVID-19) at Mass Gathering Events.

Primary Purpose

Covid19

Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
SARS-CoV-2 antigen rapid test
Sponsored by
Norwegian Institute of Public Health
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Covid19 focused on measuring COVID-19, Infection control, Rapid test

Eligibility Criteria

18 Years - 44 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Aged 18-45 years
  • Willingness to be randomised and to have a PCR-test taken a week after mass gathering event (both intervention and control groups)

Exclusion Criteria:

  • Vaccinated for COVID-19
  • Having tested positive for SARS-CoV-2 the last 6 months
  • Risk factors for severe COVID-19

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    No Intervention

    Arm Label

    Rapid test and concert

    Control

    Arm Description

    Participants in this arm will be offered access to a concert, after a negative rapid test.

    Participants in this are will not be offered access to a concert during the study period.

    Outcomes

    Primary Outcome Measures

    SARS-CoV-2 infection
    Positive PCR-test

    Secondary Outcome Measures

    Clinical COVID-19 disease
    Registered diagnosis in administrative databases
    Hospital admissions
    Registered in administrative database
    False positive rapid test
    Rapid tests that yield a positive result which is not confirmed by PCR test

    Full Information

    First Posted
    May 21, 2021
    Last Updated
    March 23, 2023
    Sponsor
    Norwegian Institute of Public Health
    Collaborators
    University of Oslo
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04898127
    Brief Title
    Antigen Rapid Test Screening to Prevent SARS-CoV-2 Transmission (COVID-19) at Mass Gathering Events.
    Official Title
    Antigen Rapid Test Screening to Prevent SARS-CoV-2 Transmission at Mass Gathering Events. A Randomised Trial.
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    May 2021
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    The study needed approval from local authorities (City of Oslo and City of Bergen) to take place, which it did not get.
    Study Start Date
    May 2021 (Anticipated)
    Primary Completion Date
    June 2021 (Anticipated)
    Study Completion Date
    December 2021 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Norwegian Institute of Public Health
    Collaborators
    University of Oslo

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    To investigate the impact of rapid antigen testing for Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2), the investigators plan to conduct a large trial to assess the impact of using rapid tests to screen people before participating at a mass gathering event, i.e. a music concert. Among participants who wish to attend and fulfill the inclusion criteria, half will be offered access to rapid testing and concert (provided the test is negative), and the other half will not. Allocation will be by randomisation. A week after the concert both groups will be tested by means of a standard PCR-test.
    Detailed Description
    To investigate the impact of rapid SARS-CoV-2 antigen testing on the incidence of COVID-19, the investigators plan to conduct a large trial to assess the impact of using rapid tests to screen people before participating a mass gathering event, i.e. a music concert. The hypothesis is that screening by means of rapid testing eliminates any increase in risk of COVID-19 from attending a mass gathering event. The investigators will recruit Individuals aged 18-45 years, who wish to attend a specific concert, have not received vaccination or had Covid-19 in the past six months, and are not in any risk group for severe disease. At recruitment, all participants (both concert and no-concert groups) will sign a consent form where they commit to using a contact tracing app, and to allowing the research group to use their data in the Norwegian Emergency Preparedness Register (BEREDT C19). They will also consent to having a COVID-19-test (PCR) conducted 6-8 days after the concert date. After placing their payment, they will be randomised to be given access to a music concert (concert group), or not (no-concert group). Those who are randomised to the concert group will be tested for SARS-CoV-2 using a rapid antigen test, shortly before the concert. Those who test positive will be excluded from attending the concert and will immediately be offered a PCR-test. All participants will be instructed to stay at home if they have symptoms of COVID-19 or are in quarantine. Participants who have symptoms or are quarantined at the time of the follow-up test will be offered a test through home visit by a mobile clinic. Infection control measures will be applied to all concert participants in line with standards established by the sector, e.g. hand hygiene measures and a logistical system that seeks to minimise the risk of transmission during entry to the arena and exit after the concert

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Covid19
    Keywords
    COVID-19, Infection control, Rapid test

    7. Study Design

    Primary Purpose
    Screening
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    Individually randomised trial.
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Rapid test and concert
    Arm Type
    Experimental
    Arm Description
    Participants in this arm will be offered access to a concert, after a negative rapid test.
    Arm Title
    Control
    Arm Type
    No Intervention
    Arm Description
    Participants in this are will not be offered access to a concert during the study period.
    Intervention Type
    Diagnostic Test
    Intervention Name(s)
    SARS-CoV-2 antigen rapid test
    Intervention Description
    Rapid test before access to mass gathering event (concert), provided the test result is negative.
    Primary Outcome Measure Information:
    Title
    SARS-CoV-2 infection
    Description
    Positive PCR-test
    Time Frame
    6-8 days after mass gathering event
    Secondary Outcome Measure Information:
    Title
    Clinical COVID-19 disease
    Description
    Registered diagnosis in administrative databases
    Time Frame
    1 to 14 days after mass gathering event
    Title
    Hospital admissions
    Description
    Registered in administrative database
    Time Frame
    1 to 3 weeks after mass gathering event
    Title
    False positive rapid test
    Description
    Rapid tests that yield a positive result which is not confirmed by PCR test
    Time Frame
    Within 24 hours.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    44 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Aged 18-45 years Willingness to be randomised and to have a PCR-test taken a week after mass gathering event (both intervention and control groups) Exclusion Criteria: Vaccinated for COVID-19 Having tested positive for SARS-CoV-2 the last 6 months Risk factors for severe COVID-19
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Atle Fretheim, PhD
    Organizational Affiliation
    Norwegian Institute of Public Health
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    We will collect very limited IPD: Beyond outcome measures, the IPD will be age, sex. These data can be shared, at the individual level.
    IPD Sharing Time Frame
    Until 31. July 2026.

    Learn more about this trial

    Antigen Rapid Test Screening to Prevent SARS-CoV-2 Transmission (COVID-19) at Mass Gathering Events.

    We'll reach out to this number within 24 hrs